HBC Immunology (HBCI) is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a i...
Survey findings from over 8,700 people in 12 countries show that half of those polled have inadequate understanding of HPV, with ne...
Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of $850 million in cash. Regor ...
New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapi...
On the eve of the International Myeloma Society (IMS) Annual Meeting, Dr. Yongke Zhang, Chief Scientific Officer of IASO Biotherapeutics (IASO Bio), along ...
Takara Bio Europe, a wholly owned subsidiary of Takara Bio Inc., announces the launch of the Shasta™ Single-Cell System at the 2024 Human Cell A...
NIH analysis of 2021 cancer incidence data finds that missed diagnoses were not accounted for What: Cancer incidence trends in 2021 larg...
The European Society for Medical Oncology (ESMO) 2024 Congress, held from September 13 to 17 in Barcelona, brought together global oncology experts to un...
AbbVie announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommen...
Vidac Pharma Holdings Plc., a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, announces that the U...
– Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Kisqali® (ribociclib) in combination with an aromata...
BeiGene, a global oncology company, announced that the Israeli Ministry of Health (IL MOH) has approved TEVIMBRA® (tislelizumab) as monotherapy for t...
Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion coho...
- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCL...
© 2024 Biopharma Boardroom. All Rights Reserved.
